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I. INTRODUCTION
The cannabis plant has been utilized as a resource by civilizations 
throughout the world over thousands of years.2 Cannabis has been used 
as medicine, fuel, food, clothing, and as a means of intoxication.3 In 
depth studies have been conducted to determine the physical and 
psychological effects of “mari[h]uana (the dried bud of the female 
plant).”4 These studies have found a few minor risks, but overall have 
discovered a multitude of benefits that can be derived from the use of 
marihuana.5 In fact, it has been stated that “the single greatest risk 
encountered by the user of marihuana in any state in this country [the 
United States] is that of being apprehended as a common criminal, 
 1. David Rudoi is an attorney at Rudoi Law in Royal Oak, Michigan. Mr. Rudoi 
presented this material at the February 19, 2016 Michigan State International Law 
Review symposium entitled “Emerging Narratives: Developments in Global Drug 
Policies.”  
 2. Leah Spicer, Historical and Cultural Uses of Cannabis and the Canadian 
“Marijuana Clash,” PARLIAMENT CAN., L. & GOV’T DIV. (Apr. 12, 2002), 
http://www.parl.gc.ca/Content/SEN/Committee/371/ille/library/Spicer-e.htm. 
 3. Id.
 4. Carolynn Conron, Canada’s Marihuana Medical Access Regulations: Up in 
Smoke, 6 ALB. GOV’T L. REV. 259, 261 (2013). 
 5. Id.
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incarcerated, and subjected to untold damage to his social life and 
career.”6
Recreational use of marihuana has been criminalized in both Canada 
and the United States for decades. However, the medical use of 
marihuana has been decriminalized in Canada since 2001, defensible in 
areas of the United States beginning in 1996, and defendable in Michigan 
following the passing of a voter initiative in 2008.7 Due to the close 
proximity and inevitable social comingling of Canada and Michigan, the 
evolution of Canadian medical and recreational marihuana regulations 
may impact parallel statutes in Michigan specifically, as well as the 
United States generally. Similarly, the accessibility of Canadians to 
Michigan and Michiganders to Canada creates an undeniable relationship 
between marihuana regulations in either location and marihuana 
consumption in the other. The question remains, will Canada’s medical 
marihuana reforms and movement towards federal decriminalization 
shift Michigan’s regulations along with the United States’ federal 
statutes in a similar direction? 
II. THE LAW
A. Canada 
The recreational use of marihuana is not permitted in Canada; 
however, residents are permitted to use cannabis for medical purposes.8
Cannabis is prescribed in Canada “for conditions such as cancer, 
multiple sclerosis, spinal cord injury, hepatitis, and arthritis . . . [as well 
as] anxiety, stress, depression, and pain.”9
 6. Ruth C. Stern & J. Herbie DiFonzo, The End of the Red Queen’s Race: 
Medical Marijuana in the New Century, 27 QUINNIPIAC L. REV. 673, 687 (2009) (quoting 
Lester Grinspoon, Associate Professor Emeritus in Psychiatry at Harvard Medical 
School).
 7. Marihuana Medical Access Regulations, SOR/2001-227 (Can.); 28 Legal 
Medical Marijuana States and DC, PROCON, http://medicalmarijuana.procon.org/ 
view.resource.php?resourceID=000881 (last updated Nov. 9, 2016, 11:49 AM); Michigan 
Medical Marihuana Act (MMMA), MICH. COMP. LAWS Ch. 333 (2008). 
 8. Legal Medical Cannabis Use in Canada, MARIJUANALAWS.CA,
http://www.marijuanalaws.ca/legal-laws.html (last visited Mar. 24, 2017). 
 9. Id.
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1. Criminalization of Marihuana 
In 1923, the Canadian Parliament amended the Opium and Narcotic 
Drug Act to include cannabis as a federally–prohibited narcotic.10 The 
current Canadian legislation barring marihuana is the Controlled Drugs 
and Substances Act (CDSA), which was passed in 1996.11 The CDSA 
prohibits, as a federal offense, the possession, trafficking, importation or 
exportation or production of any scheduled substances.12 Schedule II 
substances include,
Cannabis, its preparations and derivatives, including[;] (1) Cannabis 
resin, (2) Cannabis (marihuana), (3) Cannabidiol . . . (4) Cannabinol . . . 
(7) Tetrahydrocannabinol . . . but not including (8) Non–viable 
Cannabis seed, with the exception of its derivatives, (9) Mature 
Cannabis stalks that do not include leaves, flowers, seeds or branches; 
and fiber derived from such stalks.13
If a person is found possessing, selling, producing, or 
importing/exporting cannabis, under the CDSA they may be incarcerated 
for up to five years.14 Furthermore, if a defendant is found guilty of 
trafficking cannabis they may receive a penalty of life in prison.15 Under 
the CDSA, “[t]rafficking is a ‘designated substance offense,’ which is 
proven once a person is found to have given or delivered a drug to 
another.”16 Moreover, trafficking may be established for minor behaviors 
such as handing a small amount of marihuana to a person.17 Although, a 
transformation in public opinion of marihuana began in the 1960s when 
its use increased, and numerous young people were being subjected to 
drug investigations, criminal charges and arrests continue to persist.18
 10. Diane Riley, Drugs and Drug Policy in Canada: A Brief Review & 
Commentary, CANADIAN FOUNDATION FOR DRUG POLICY & INTERNATIONAL HARM 
REDUCTION ASSOCIATION, Prepared for the Senate of Canada (Nov. 1998).  
 11. See generally Controlled Drugs and Substances Act, S.C. 1996, c 19 (Can.). 
 12. Id. pt. 1; Conron, supra note 4, at 263. 
 13. Controlled Drugs and Substances Act, sched.. II, § 1(9) (emphasis added). 
 14. Id. pt. I, § 4, sched. VIII. 
 15. Id. pt. I, §5(3). 
 16. Conron, supra note 4, at 264 (quoting R. v. Larson (1972), 6 C.C.C. 2d 145 
(Can. B.C. C.A.)). 
 17. Id. (citing R. v. Lauze (1980), 17 C.R. 3d 90 (Can. Que.)). 
 18. Id. at 263. 
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2. The Beginning of Reform 
In 1997, Terrance Parker, a Canadian citizen, was charged with 
possession of marihuana following a doctor’s prescription of marihuana 
as medicine for Parker’s epilepsy.19 Parker was forced to grow his own 
medical marihuana when he was unable to find the medicine any other 
way and was subsequently caught with the “contraband.”20 Parker 
appealed the charge, claiming that it violated his rights under the 
Canadian Charter of Rights and Freedoms (the Charter).21 Section 7 of 
the Charter guarantees every person “the right to life, liberty and security 
of the person and the right not to be deprived of those rights except in 
accordance with the principles of fundamental justice.”22
Parker had severe epilepsy and had suffered from the disease for close 
to forty years at the time he was arrested.23 Parker tried to control his 
seizures with surgeries and other forms of medicine; however, these 
treatments were only moderately successful at alleviating his 
symptoms.24 Smoking marihuana “substantially reduce[d] the incidence 
of [Mr. Parker’s] seizures.”25 The medicinal value of marihuana was 
known at this time, yet there was no legal way to obtain the drug.26 A 
company could have applied for a license to sell versions of marihuana 
components, such as Canabidiol (CBD), but aside from a synthetic 
version of tetrahydrocannabinol (THC), no company had done so at that 
time.27 Consequently, Parker began growing the life-changing medicine 
himself and was subsequently arrested for violating the Narcotics 
Control Act, and later the Controlled Drugs and Substances Act.28
Parker fought the charges, and the Ontario Court of Justice found that 
in fact, Parker did need the marihuana to manage his epilepsy and that 
his rights had been violated under section 7 of the Charter.29 Moreover, 
 19. Regina v. Parker (1997), 49 O.R. 3d 481, 490 (Can. Ont. C.A.).  
 20. Id. at 487. 
 21. Id.
 22. Id.
 23. Id.
 24. Id.
 25. Parker, 49 O.R. 3d at 490. 
 26. Id.
 27. Id.
 28. Id.
 29. Id. at 488.  
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to protect Parker and others like him who need marihuana as medicine, 
“the trial judge read into the legislation an exemption for persons 
possessing or cultivating marijuana for their ‘personal medically 
approved use.’”30 The Court of Appeals of Ontario upheld this decision 
in 2000 and “concluded that the prohibition on the cultivation and 
possession of marijuana is unconstitutional” in Canada.31
Nonetheless, the Court of Appeals of Ontario stated that the new 
legislation should be established by the Parliament, not the court, and 
provided one year for Parliament to amend the current statute so as not to 
be in violation of the Charter.32 Parliament’s response came in the form 
of the Marihuana Medical Access Regulations.33
B. Marihuana Medical Access Regulations (MMAR)  
The Marihuana Medical Access Regulations (MMAR) were originally 
enacted in July 2001.34 The Marihuana Medical Access Regulations 
authorized possession of dried marihuana, “for the medical purpose of 
the holder.”35 The permitted medical conditions enumerated in these 
regulations include cancer, AIDS/HIV, multiple sclerosis, spinal cord 
injury or disease, epilepsy, and severe forms of arthritis.36 MMAR also 
allows for the use of medical marihuana to treat symptoms caused by 
these specified medical conditions.37 A Canadian resident over the age of 
18 may possess medical marihuana once they have received an 
authorization from the Minister, and may manufacture marihuana if they 
have a license to produce.38
 30. Id. at 481.  
 31. Parker, 49 O.R. 3d at 489. 
 32. Id.
 33. See Marihuana Medical Access Regulations, SOR/2001-227, § 2 (Can.) 
[hereinafter MMAR]. 
 34. Id. pt. 4, § 73.  
 35. Id. pt. 1, § 2. 
 36. Id. sched. [1]. 
 37. Id.
 38. Id. pt. 2, § 35(a). 
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1. Possession of Medical Marihuana 
In order to be eligible to possess marihuana under the MMAR, a 
person must ordinarily reside in Canada and obtain authorization to 
possess by the Canadian government through an application sent to the 
Minister.39 The application for authorization must include “a declaration 
of the applicant . . . a medical declaration made by the medical 
practitioner treating the applicant; and . . . two copies of a current 
photograph of the applicant.”40 The declaration must certify that the 
applicant is aware that no notice has been issued “concerning the safety 
and effectiveness of marihuana as a drug.”41 The applicant must also 
certify that they: (1) have “discussed the potential risks” and benefits of 
marihuana use with their medical professional; (2) are aware these risks 
are not fully understood or identified; and (3) accept these risks.42
Finally, the applicant must assert, “that [the] marihuana will be used only 
for the treatment of the symptom stated for the applicant.”43
The medical declaration is fairly detailed and must include itemized 
information about the applicant’s medical condition.44 The medical 
professional must explain the applicant’s medical condition; the 
symptom(s) the condition or treatment causes; the maximum amount of 
marihuana authorized; the daily amount of marihuana and the method of 
use the applicant intends to use; and the “anticipated period of usage, if 
less than 12 months.”45 Additionally, the medical professional must 
affirm that the applicant has tried the conventional methods of treatment 
and they are either “ineffective or medically inappropriate for . . . the 
applicant.”46
 39. MMAR, pt. 1, §§ 3-4. 
 40. Id. pt. 1, § 4(2)(a)–(c). 
 41. Id. pt. 1, § 5(1)(f). 
 42. Id. pt. 1, § 5(1)(f), (i). 
 43. Id. pt. 1, § 5(1)(j). 
 44. See id. pt. 1, §§ 6, 8. 
 45. MMAR. pt. 1, § 6(1)(b)–(d). 
 46. Id. pt. 1, § 6(2)(b)(v). 
2017] Medical Marihuana Law Development in Canada and Michigan 341
2. Production of Medical Marihuana 
A person may produce marihuana for their own medical purposes 
once he or she has obtained a personal-use production license.47 In order 
to obtain this license, an individual must ordinarily reside in Canada and 
be over the age of 18.48 An individual with a personal-use production 
license may produce marihuana in his or her ordinary place of residence, 
or at a site that is not his or her ordinary residence if he or she has a 
signed declaration from the owner consenting to the production.49 A 
personal-use producer may produce marihuana indoors or outdoors; 
however, if the production is partly outdoors then “the production site 
[may] not [be] adjacent to a school, public playground, day care facility 
or other public place frequented mainly by persons under 18 years of 
age.”50
Once an individual is granted a personal-use production license, the 
number of marihuana plants and amount of dried marihuana he or she is 
allowed to produce is determined by a formula that takes into account 
whether the marihuana is grown indoors, outdoors, or partially both.51
Ultimately, these formulas are complex and can be confusing for 
personal-use producers, and could result in unintentional violations of the 
law.52
 47. Id. pt. 2, § 24. 
 48. Id. pt. 2, § 25(1). 
 49. Id. pt. 2, § 27(1)–(2). 
 50. Id. pt. 2, § 28(1)(g). 
51. MMAR, pt. 2, § 30.  
 52. For purposes of the following formulas, A stands for “the daily amount of 
dried marihuana [permitted], in grams,” B is the expected yield of each plant, and C is 
“the growth cycle of a marihuana plant from seeding to harvesting;” C is a constant that 
is always 1. The formulas are broken down based on the growth cycle of the plant, the 
expected yield per plant, and whether the plants are grown inside, outside, or a 
combination of both. Id. “If the production area is entirely indoors,” the expected yield of 
each plant (B) is 30 grams, and the formula is: The maximum number of plants= [A x 
365] y [(B x 3C)] x 1.2. Id. pt. 2, § 30(2)(a). If the production is entirely outdoors, B is 
equal to 250 grams, the formula is: “D= [(A x 365) y (B x C)] x 1.3. Id. pt. 2, § 30(2)(b). 
Where production occurs “pt.ly indoors and partly outdoors,” the formula “for the indoor 
period” is: D = [(A x 182.5) y (B x 2C) x 1.2 where 30 grams is the expected yield, and 
the outdoor portion follows the formula: D = [(A x 182.5) y (B X C)] x 1.3 where the 
expected yield is 250 grams. Id. pt. 2, § 30(2)(c). Where the formula produces a fraction, 
the number is to be rounded up. Id pt. 2, § 30(4). 
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A person may obtain a designated-person production license to 
produce marihuana for the medical use by another person.53 An 
individual is eligible for this type of license as long as they have never 
“been found guilty, as an adult, within the 10 years preceding the 
application, of . . . a designated drug offence, or” an offense that would 
have been a drug offense in Canada.54 A Designated-Person Production 
License permits an individual to transport marihuana from the site of 
production directly to the residence of the licensed individual.55 The 
Designated-Person must not send more than the maximum quantity 
granted in the right to possess, and the dried marihuana must be securely 
packaged in a way that it is indistinguishable, and will not be opened 
without breaking a seal.56
3. Role of Law Enforcement in the Regulations 
Generally, an officer may demand a holder of a license to possess, or 
a license to produce, to display their license at any time.57 However, the 
Marihuana Medical Access Regulations do not specifically provide 
defenses or prohibitions on arrest or prosecution of authorized users or 
producers of medical marihuana.58 In 2013, the Canadian Parliament 
passed a new set of medical marihuana regulations, the Marihuana for 
Medical Purposes Regulations, which significantly altered the ways in 
which a person may obtain medical marihuana.59
C. Marihuana for Medical Purposes Regulations (MMPR) 
The Marihuana for Medical Purposes Regulations (MMPR) were 
adopted on June 6, 2013 as an annex to the Controlled Drugs and 
Substance Act.60 The new Marihuana for Medical Purposes Regulations 
 53. MMAR, pt. 2, § 34(1)(a). 
 54. Id. pt. 2, § 35(b). 
 55. Id. pt. 2, § 34(1)(d). 
 56. Id. pt. 2, § 34. 
 57. Id. pt. 3, § 58. 
 58. See generally MMAR. 
 59. See generally Marihuana for Medical Purposes Regulations, SOR/2013-119 
(Can.) [hereinafter MMPR]. 
60. Access to Cannabis for Medical Purposes Regulations, SOR/2016-230 (Can.).
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effectively terminated the previous Marihuana Medical Access 
Regulations.61 These new medical marihuana protocols shift production 
away from personal home growing and toward corporate industrial 
production of medical marihuana.62
1. Possession of Medical Marihuana 
Similar to the MMAR, the MMPR permits a person to possess dried 
marihuana if they have “obtained the dried marihuana for their own 
medical purposes or for those of another person for whom they are 
responsible.”63 This dried marihuana may be purchased “from a licensed 
producer, in accordance with a medical document . . . from a health care 
practitioner in the course of treatment for a medical condition, or . . . 
from a hospital.”64 Dried marihuana is vaguely defined as, “harvested 
marihuana that has been subjected to any drying process.”65
The MMPR also permits a person to possess dried marihuana if he or 
she is a healthcare practitioner, a hospital employee, or a licensed 
producer using it in the course of his or her profession or employment.66
Moreover, an individual may possess a portion of a patient’s dried 
marihuana, not exceeding the daily quantity of dried marihuana the 
patient is authorized to possess, if he or she is providing assistance in the 
administration of the marihuana as medicine.67
Possession of cannabis is also permitted under certain 
circumstances.68 The MMPR adopted the Controlled Drug and 
Substances Act’s classification of cannabis as; “Cannabis, its 
preparations and derivatives including Cannabis resin, Cannabis 
(marihuana), Cannabidiol . . . but not including Non-viable Cannabis 
seed, with the exception of its derivatives[,] Mature Cannabis stalks that 
 61. Id.
 62. See generally id; see infra § II(3)(b) Production of Medical Marihuana. 
 63. MMPR, § 3(2)(a). 
 64. Id.
 65. Id. pt. 1, § 1(1). 
 66. Id. pt. 1, § 3(2)(b), (c). 
 67. Id. pt. 1, § 3(6). 
 68. Id. pt. 1, § 4(1), (2). 
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do not include leaves, flowers, seeds or branches; and fiber derived from 
such stalks.”69
a.  Possession Limitations  
The MMPR limits the quantity of dried marihuana an individual may 
possess to no more than thirty times their daily dose, as determined by a 
health care practitioner or hospital, which may not exceed 150 grams.70
2. Production of Medical Marihuana 
A large portion of the MMPR focuses on licensed producers.71 A 
licensed producer of marihuana has the ability to “possess, produce, sell, 
provide, ship, deliver, transport and destroy marihuana.”72 They also 
have permission to possess and produce cannabis, that is not marihuana, 
for the purposes of testing and may then “sell, provide, ship, deliver, 
transport and destroy [that] cannabis . . . [which] was obtained or 
produced solely for” the testing.73
A licensed producer is permitted to “sell or provide dried marihuana 
to” clients or their caregiver, hospital staff for use within their 
employment, or any person the Minister permits due to medical or 
scientific need.74 However, none of these transactions may occur within a 
dwelling, and must occur in the place specified on the producer’s 
license.75 In order to be eligible to apply for a producer’s license, a 
person must be “an adult who ordinarily resides in Canada; [or] . . . a 
corporation that has its head office in Canada or operates a branch office 
in Canada and whose officers and directors are all adults.”76
The application for a producer’s license must be submitted to the 
Minister.77 The application is extensive and includes general identifying 
 69. Controlled Drugs and Substances Act, S.C. 1996, c 19, sched. II (Can.) 
(emphasis added). 
 70. MMPR, § 5; id. pt. 5, § 129. 
 71. See generally id. pt. 1. 
 72. Id. pt. 1, § 12(1)(a). 
 73. Id. pt. 1, div. 1, § 12(1)(c). 
 74. Id. pt. 1, div. 1, § 12(4)(a). 
 75. Id. pt. 1, div. 1, § 13. 
 76. MMPR, pt. 1, div. 2, § 21. 
 77. Id. pt. 1, div. 2, § 23(1). 
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information of the individual or company, the “name, date of birth and 
gender of . . . the proposed senior person in charge,  . . . [and] the 
proposed responsible person in charge,” along with the “name and 
gender of each of the persons authorized” to order cannabis for the 
applicant.78 In addition, the application also requires a considerable 
amount of more detailed information including, “the proposed activities 
that are to be conducted at each building . . . a detailed description of the 
security measures . . . [and] a detailed description of the methods that the 
applicant proposes to use for keeping records,” along with an agreement 
to give the Minister access to the site.79 Applicants must also provide the 
maximum quantity (in kilograms) of dried marihuana they plan to 
produce under the license, their production period, and “the maximum 
quantity ( . . . in kilograms) of dried marihuana to be sold or provided by 
the applicant under the licence.”80 If the applicant for a producer’s 
license intends to have more than one site, he or she must complete a 
separate application for each proposed site.81 Finally, the applicant must 
attach multiple signed documents including, among other things, an 
affirmation from the senior person in charge stating they claim 
responsibility; copies of any document filed with the province in which 
they plan to have a site; a declaration that the senior person owns the 
entire proposed site or a declaration signed by the owner consenting to 
the proposed use; a declaration that the site is not a “dwelling place;” a 
declaration stating that notices to local authorities have been provided 
specifying the names of the officials and dates they were contacted; and 
floor plans for the proposed site.82
Once a person or corporation has been approved as a licensed 
producer, they must designate one senior person to have responsibility 
for the activities carried out by the producer.83 In addition, the licensed 
producer must designate a person, physically present, at the site of 
production, to be in charge and have responsibility for their activities, 
ensuring they comply with their license and the Food and Drugs Act.84
 78. Id. pt. 1, div. 2, § 23(1)(d)–(e). 
 79. Id. pt. 1, div. 2, § 23(1)(g)–(i). 
 80. Id. pt. 1, div. 2, § 23(1)(k). 
 81. Id. pt. 1, div. 2, § 23(2). 
 82. MMPR, pt. 1, div. 2, § 23(4).
 83. Id. pt. 1, div. 2, §§ 21, 22(1)(a). 
 84. Id. pt. 1, div. 2, § 22(1)(b). 
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These designated persons, as well as the individual or officers and 
directors of the corporation, must hold a security clearance with the 
Canadian government.85
After an applicant has submitted a complete producer’s license 
application, “the Minister must, after examining the information and 
documents required . . . and after all of the security clearances required . . 
. have been granted . . . issue to the applicant a producer’s licence.”86 The 
producer’s license may be effective for no more than three years before 
an individual or corporation must renew.87 However, the Minister must
refuse issue or renewal of a producer’s license if the applicant is not a 
resident of Canada, the applicant did not comply with the requirements 
before submitting the application, or the issue or renewal would “likely 
create a risk to public health, safety or security, including the risk of 
cannabis being diverted to an illicit market or use.”88 The Minister is 
permitted to request additional information before granting or denying a 
producer’s license or renewal.89
a. Security of the Production Site  
A licensed producer’s site must be designed in a way that prevents 
unauthorized access.90 The site “must be visually monitored at all times 
by visual recording devices[;]”91 in addition, “[t]he perimeter of the 
licensed producer’s site must be secured by an intrusion detection system 
that operates at all times and that allows for the detection of any 
attempted or actual unauthorized access” and must be monitored at all 
times by personnel.92 Records must be kept of any unauthorized access 
and how the licensed producer responded to these incidents.93
Only those employees whose work responsibilities require them to be 
present are allowed in areas where cannabis is present, and the 
 85. Id. pt. 1, div. 2, § 24. 
 86. Id. pt. 1, div. 2, § 25 (emphasis added). 
 87. See id.
 88. MMPR, pt. 1, div. 2, §26(h). 
 89. Id.
 90. See id. pt. 1, div. 3, § 41. 
 91. Id. pt. 1, div. 3, §43(1). 
 92. Id. pt. 1, div. 3, §§ 43, 44, 45(1). 
 93. Id. pt. 1, div. 3, § 45(2). 
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responsible person in charge must accompany those employees.94
Additionally, areas with cannabis present must keep record of every 
person entering and exiting the area, have physical barriers preventing 
access, and monitor “visual recording . . . to detect illicit conduct.”95
b. Clients  
A licensed producer is able to sell dried marihuana to an unlimited 
number of clients; however, their clients must “ordinarily reside in 
Canada.”96 Before an individual may become a client, they, or an 
individual responsible for them, must submit an application to the 
licensed producer.97 The application must include the applicant’s general 
identifying information, the address at which they ordinarily reside in 
Canada—or the name of the place they receive “food, lodging or other 
social services” if they do not have a residence—and a shipping address 
if it is different.98 The applicant, or the person responsible for them, must 
also include their medical document and a signature affirming,  
the applicant is ordinarily [a] resident in Canada; [] the information in 
the application and the medical document is correct and complete; [] 
the medical document is not being used to seek or obtain dried 
marihuana from another source; [] the original of the medical document 
accompanies the application; and [] the applicant will use dried 
marihuana only for their own medical purposes.99
The licensed producer must ensure the authenticity of the medical 
document and verify it was “provided by a health care practitioner to a 
person who is under their professional treatment.”100 The medical 
practitioner must indicate, their general information,  
the province in which the practitioner is authorized to practise[,] their 
profession and the[ir authorization] number . . . the [applicant client’s] 
 94. MMPR, pt. 1, div. 3, § 46(1)–(2). 
 95. Id. pt. 1, div. 3, §§ 46(3), 47, 48(1). 
 96. Id. pt. 2, § 107. 
 97. Id. pt. 2, § 108(1). 
 98. Id. pt. 2, § 108(1). 
 99. Id. pt. 2, § 108(3). 
 100. MMPR, pt. 4, § 129(1). 
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given name, surname and date of birth; [] the address of the . . . 
consult[ation] with the practitioner; [] the daily quantity of dried 
marihuana to be used by the person, expressed in grams; and [] the 
period of use.101
A client is required to provide a new medical document to the 
licensed producer every year.102
Once the information in the medical document and on the client 
application is confirmed, the licensed producer may register the 
individual as a client.103 The licensed producer must then send the client 
a registration document with the name of the producer, the client’s 
general information, and a “unique identifier for the purpose of ordering 
dried marihuana.”104 Conversely, the licensed producer must terminate 
the registration of a client in the following circumstances: the client, or 
someone responsible for them, tells the producer to cancel the 
registration; “the client dies, ceases to be ordinarily [a] resident in 
Canada or ceases to have a shipping address in Canada; [] the licensed 
producer has reasonable grounds to believe” the application was made 
using false or misleading information; or “the health care practitioner 
who provided the medical document to the client is named in a notice 
issued under . . . the Narcotics Control Regulations” that prohibits dried 
marihuana from being shipped to them.105
c. Processing Orders  
Prior to fulfilling an order for a client, a licensed producer must first 
receive a dated order, in writing, for dried marihuana that provides the 
client’s and the person making the order’s name, date of birth, the 
shipping address, and the client’s unique identifier, along with “the 
quantity and the brand name of the dried marihuana being ordered.”106
When fulfilling the order, a licensed producer may only provide the dried 
 101. Id.
 102. Id. pt. 4, § 129(2)–(3). 
 103. Id. pt. 2, § 111(1). 
 104. Id. pt. 2, § 111(2). 
 105. Id. pt. 2, § 117(1); Narcotics Control Regulations, C.R.C., c 1041 (Can.). 
 106. MMPR, pt. 2, § 121(2). 
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marihuana by shipping it to the client’s address.107 A client may only 
seek and obtain dried marihuana from one source at a time.108 The 
regulations also limit the ways in which dried marihuana may be sold.109
The sale of dried marihuana is prohibited “in any dosage form, such as in 
a roll or capsule.”110
Further, the licensed producer must adhere to a multitude of 
packaging requirements when shipping dried marihuana.111 For example, 
the packaging must be “in direct contact with the dried marihuana . . . 
keep[] the [] marihuana dry and free from contamination,” provide 
security from being opened in transit, be child resistant, and hold no 
more than 30 grams of marihuana.112 The package must also have a label 
with several required specific identifiers, including: the name of the 
licensed producer; the marihuana brand name; lot number; net weight; 
percentage of cannabinoids; recommended storage conditions; packaging 
date; the symbol “N”; the words “Dried marihuana/ Marihuana séchée;” 
warnings to keep away from children; and instructions to consult the 
Health Canada document.113
3. Violations of the MMPR 
The MMPR provides immunity for the licensed producers and 
patients who are medically prescribed marihuana.114 The CDSA creates 
exceptions where the Minister is able to exempt any controlled substance 
under the Act if “the exemption is necessary for a medical or scientific 
purpose or is otherwise in the public interest.”115 In accordance with this 
allowance, medical marihuana is exempt from the CDSA’s prohibition of 
the use of marihuana in non-medical situations.116 However, stringent 
regulations have been instituted in order to ensure strict adherence to the 
MMPR regulations, and producers are regularly inspected by Health 
 107. Id. pt. 2, § 122. 
 108. Id. pt. 3, § 126. 
 109. See Id. § 6(1). 
 110. Id. § 6(1)(b). 
 111. See id. pt. 1, div. 5.  
 112. MMPR, pt. 1, div. 5, § 64. 
 113. Id. pt. 2, div. 5, §66. 
 114. See generally MMPR. 
 115. Controlled Drugs and Substances Act, S.C. 1996, c. 19, § 56(1) (Can.). 
 116. Id.
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Canada.117 Furthermore, if a patient is found to possess more marihuana 
than the 150 gram maximum, they may be charged with possession of 
cannabis under the Controlled Drugs and Substances Act.118
As a result of these new regulations the medical industry in Canada 
has experienced a shift towards a commercial paradigm that is regulated 
much like the current practice with prescription drug retailers.119
Consequently, the price and daily dose of marihuana are both anticipated 
to rise dramatically in adaptation of the new regulations.120 For example, 
the recommended average daily dose may increase in order for 
consumers to maintain a supply to last them longer than the allowed 30 
days.121 Furthermore, there have been changes made to the MMPR, 
Canadian case law, and the Canadian Government that have created an 
unwillingness of law enforcement to prosecute marihuana possession.  
a. Judicial Changes in the MMPR 
In 2015, the Supreme Court of Canada found that the allowance for 
medical marihuana patients to possess and use only dried marihuana, 
with the continued prohibition of all other forms of marihuana, was 
against the Charter of Rights.122 In R. v. Smith, the defendant, Owen 
Edward Smith, was employed by Cannabis Buyers Club (The Club), 
which sold marihuana and cannabis products to members of The Club.123
In order to become a member, a person was required to show The Club 
that they had a bona fide medical condition qualifying them for use of 
medical marihuana, as indicated by a physician.124 The Club sold dried 
marihuana along with edible products, “cookies, gel capsules, rubbing 
oil, topical patches, butters and lip balms[,]” along with “recipe books for 
how to make . . . products by extracting the active compounds from dried 
 117. Archived-Accessing Marijuana for Medical Purposes- Information Bulletin,
HEALTH CAN., http://www.hc-sc.gc.ca/dhp-mps/marihuana/info/
licencedproducer-producteurautorise/access-usage-eng.php (last visited Apr. 24, 2017). 
 118. Possession of Marihuana, CAN. B. ASS’N, http://www.cbabc.org/For-the-
Public/Dial-A-Law/Scripts/Criminal-Law/201 (last visited Mar. 31, 2017).  
 119. Conron, supra note 4, at 287. 
 120. Id.
 121. Id.
 122. R. v. Smith, [2015] 2 S.C.R. 602 (Can.). 
 123. Id. at 607. 
 124. Id.
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marihuana.”125 Smith’s job was to extract chemicals from the cannabis 
plant in order to produce the edibles and other cannabis derivatives sold 
by The Club.126 Smith was not a medical marihuana user and the Club 
was not licensed to produce under the MMAR.127
A complaint was made to police regarding an “offensive smell,” and 
upon investigation, police discovered cookies, dried marihuana, and 
liquids labeled as “massage oil” and “lip balm”.128 Testing showed the 
seized evidence contained THC, which was not protected under the 
MMAR.129 Smith was charged with “possession of THC for the purpose 
of trafficking . . . and possession of cannabis.”130
Smith challenged the charges against him claiming the permission to 
use only dried marihuana medicinally was a violation of the Charter.131
The trial court held, “The active compounds of the cannabis plant, such 
as THC and cannabidiol [CBD], have established medical benefits and 
their therapeutic effect is generally accepted, although the precise basis 
for the benefits has not yet been established.”132 The trial court further 
explained:  
Different methods of administering marihuana offer different medical 
benefits. For example, oral ingestion of the active compounds, whether 
by way of products baked with THC-infused oil or butter, or gel 
capsules filled with the active compounds, may aid gastro-intestinal 
conditions by direct delivery to the site of the pathology. Further, oral 
administration results in a slower build-up and longer retention of 
active compounds in the system than inhaling, allowing the medical 
benefits to continue over a longer period of time, including while the 
patient is asleep. It is therefore more appropriate for chronic 
conditions.133
 125. Id.
 126. Id.
 127. Id. at 607–08. 
 128. Smith, 2 S.C.R. at 608. 
 129. Id.
 130. Id.
 131. Id.
 132. Id.
 133. Id. at 609. 
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In addition, the trial court noted the negative effects of inhaling 
marihuana smoke, such as the introduction of carcinogens.134 The trial 
judge held the prohibition against the medicinal use of marihuana in any 
form other than dried was a violation of the medical marihuana user’s 
liberty.135 Moreover, he held that “limiting the medical exemption to 
dried marihuana does little or nothing to enhance the state’s interest in 
preventing diversion of illegal drugs or in controlling false and 
misleading claims of medical benefit.”136 Therefore the prohibition was 
unjustified under the Charter.137
The Court of Appeals upheld the trial court’s decision.138 The 
Supreme Court of Canada found that the restriction of medicinal use to 
dried marihuana only limited Canadian citizens’ rights in multiple 
ways.139 The Court held that, “by forcing a person to choose between a 
legal but inadequate treatment and an illegal but more effective choice, 
the law also infringes [on the] security of the person.”140
It appears that the Supreme Court of Canada’s decision in R. v. Smith
has paved the way for more extensive reform of marihuana use in 
Canada.
D. Proposed Decriminalization of Marihuana in Canada 
As of April 2016, Prime Minister Justin Trudeau promised that his 
government would legalize recreational marihuana use in Canada.141 Jane 
Philpott, the Canadian Health Minister, has stated that Canada’s 
government “will introduce legislation to decriminalise and regulate 
recreational marijuana in spring 2017.”142 Though there appears to be a 
shift towards decriminalization of recreational marihuana, only time will 
 134. Smith, 2 S.C.R. at 609. 
 135. Id.
 136. Id. (internal quotations omitted). 
 137. Id. at 610. 
 138. Id.
 139. Id. at 612. 
 140. Smith, 2 S.C.R. at 613. 
 141. Reuters in Toronto, Canada to Introduce Legislation to Decriminalize 
Recreational Cannabis, THE GUARDIAN (Apr. 20, 2016, 12:38pm), 
https://www.theguardian.com/world/2016/apr/20/canada-legislation-decriminalize-
recreational-cannabis-weed-marijuana. 
 142. Id.
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show if and how recreational marihuana may be legally consumed in 
Canada.
E. The United States 
1. Federal Criminalization of Marihuana 
In the early 1900s marihuana was not prevalent in the United States, 
nor was its existence popularly known.143 Around that time, Mexican 
workers were bringing over marihuana into Texas and California.144
Once cannabis was introduced to these states its use spread amongst 
minorities and across multiple states.145 It is suspected that the fear of 
migrant workers led to a ban on marihuana, the migrants’ choice 
relaxation aide.146 Initially, cannabis was banned in El Paso, Texas in 
1914.147 By 1930, the distribution of cannabis was banned in twenty-four 
states, but the medicinal use of the plant was still permitted.148 It was not 
until 1920 when marihuana took the hardest hit in the United States.149
“In 1920, Dr. Oscar Dowling of the Louisiana Board of Health warned 
the governor and, subsequently, the U.S. Surgeon General about the 
powerful narcotic that caused exhilaration, intoxication [and] delirious 
hallucinations.”150 In the early 1930s physicians began publishing articles 
describing the use of marihuana as a prelude to violence and criminal 
acts, paving the way for Federal illegality.151 First, The Marihuana Tax 
Act of 1937 was passed, which essentially banned the use and sale of 
marijuana.152 This Act was ultimately found unconstitutional and 
replaced with the Controlled Substances Act in 1970, which prohibited 
 143. Stern & DiFonzo, supra note 6, at 680. 
 144. Id.
 145. Id.
 146. Id.
 147. Id.
 148. Id.
 149. Stern & DiFonzo, supra note 6, at 680. 
 150. Id. (internal quotations omitted). 
 151. Id. at 681–82. 
 152. David Solomon, The Marihuana Tax Act of 1937,
http://www.druglibrary.org/schaffer/hemp/taxact/mjtaxact.htm (last visited Apr. 25, 
2017).
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the use of substances based on schedules.153 This Act categorized 
cannabis as a Schedule I drug, which was reserved for the most 
dangerous and potentially addictive substances with no accepted medical 
use.154 Originally, cannabis was only labeled a schedule I substance until 
a report on its potential for danger could be compiled.155 However, even 
after a recommendation that marijuana was not an illicit substance and 
should not be a Schedule I drug, it remains in this category.156
2. The Michigan Medical Marihuana Act (MMMA) 
Like the Federal Controlled Substance Act, the State of Michigan 
categorizes Cannabis as a schedule I substance and prohibits the 
manufacture, delivery, and possession of marijuana.157 In 2008, per a 
voter referendum, the State of Michigan created a criminal defense for 
the medical use of marijuana.158 Based on findings that marihuana does 
in fact provide significant medicinal benefits to patients, the state of 
Michigan now permits the use of marihuana to treat specified medical 
ailments, such as “[c]ancer, glaucoma, [HIV], acquired immune 
deficiency syndrome, hepatitis C, amyotrophic lateral sclerosis, Crohn’s 
disease, agitation of Alzheimer’s disease, nail patella, or the treatment of 
these conditions.”159 The MMMA relies on modern medical research and 
the scientifically proven medicinal benefits of marihuana and the active 
compounds found within it.160 The MMMA’s primary focus is on the 
immunities and defenses provided for individuals who are licensed to 
possess and produce marihuana for medical purposes.161
Outright, the MMMA addresses the potential conflict between the 
State of Michigan’s defense for marihuana use and the United States’ 
 153. Malik Burnett & Amanda Reiman, How Did Marijuana Become Illegal in the 
First Place? (Oct. 9, 2014), http://www.drugpolicy.org/blog/how-did-marijuana-become-
illegal-first-place. 
 154. Id.
 155. Id.
 156. Id.
 157. MICH. COMP. LAWS §§ 333.7212, 333.7401 (2008). 
 158. See Michigan Medical Marihuana Act, MICH. COMP. LAWS § 333.26421 
(2008) [hereinafter MMMA]. 
 159. Id. § 333.26423(b)(1). 
 160. Id. § 333.26422(a). 
 161. See generally id. § 333.26421. 
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federal prohibition against any marihuana use. Specifically the MMMA 
states, “[a]lthough federal law currently prohibits any use of marihuana 
except under very limited circumstances, states are not required to 
enforce federal law or prosecute people for engaging in activities 
prohibited by federal law.”162 Furthermore, the MMMA explains that 
statistics show that the majority of marihuana arrests are made under 
state statutes rather than federal laws.163 The MMMA goes on to reiterate 
that, “[t]he laws of Alaska, California, Colorado, Hawaii, Maine, 
Montana, Nevada, New Mexico, Oregon, Vermont, Rhode Island, and 
Washington do not penalize the medical use and cultivation of 
marihuana. Michigan joins in this effort for the health and welfare of its 
citizens.” 164
a. Permission to Possess Marihuana Under the MMMA 
The MMMA allows for a qualifying patient, who has been licensed 
and registered under the Act, to possess up to 2.5 ounces of usable 
marihuana, up to twelve marihuana plants, if they have not designated a 
primary caregiver, and any amount of stalks, seeds or unusable roots.165
Each patient may designate a caregiver to provide medical marihuana for 
him– or herself if they choose not to grow their own.166 However, if a 
patient designates a caregiver they are then unable to cultivate their own 
plants.167 All marihuana plants must be in an enclosed, locked, facility at 
all times.168
Though the MMMA is not entirely specific or lengthy, it does provide 
several definitions to clarify some of the key terms used throughout the 
Act. For instance, the definition of marihuana is taken directly from the 
Michigan Public Health Code and defined as, “all parts of the plant 
Cannabis sativa L., growing or not; the seeds of that plant; the resin 
extracted from any part of the plant; and every compound, manufacture, 
salt, derivative, mixture, or preparation of the plant or its seeds or 
 162. Id. § 333.26422(c). 
163. Id. § 333.26422(b). 
 164. MMMA, § 333.26422(c). 
 165. Id. § 333.26424(a). 
 166. Id.
 167. See id.
 168. Id.
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resin.”169 In contrast, usable marihuana is defined as, “the dried leaves 
[and] flowers . . . of the marihuana plant, [and any mixture or preparation 
thereof,] but does not include the seeds, stalks, and roots of the plant.”170
The aforementioned enclosed locked facility “means a closet, room, or 
other comparable, stationary, and fully enclosed area equipped with 
secured locks or other functioning security devices that permit access 
only by a registered primary caregiver or registered qualifying 
patient.”171 A qualifying patient is, “a person who has been diagnosed by 
a physician as having a debilitating medical condition.”172
In order to become licensed as a patient under the MMMA, a person 
must provide to the Department of Licensing and Regulatory Affairs 
(LARA): “(1) [a] written certification; (2) Application or renewal fee; (3) 
Name, address [unless homeless], and date of birth of the qualifying 
patient, . . . (4)” general contact information for the patient’s physician; 
(5) general information for the planned caregiver (if any), including 
proof that the person is allowed to possess the marihuana for medical 
use, and (6) “[p]roof of Michigan residency.”173 The written certification 
is,
a document signed by a physician, stating all of the following: 
(1) The patient’s debilitating medical condition. 
(2) The physician has completed a full assessment of the patient’s 
medical history and current medical condition, including a relevant, in-
person, medical evaluation. 
(3) In the physician’s professional opinion, the patient is likely to 
receive therapeutic or palliative benefit from the medical use of 
marihuana to treat or alleviate the patient’s debilitating medical 
condition or symptoms associated with the debilitating medical 
condition.174
 169. MICH. COMP. LAWS § 333.7106(4) (2015).  
 170. MMMA, § 333.26423(n) (emphasis added).    
 171. Id. § 333.26423(d). 
 172. Id. § 333.26423(l). 
 173. Id. § 333.26426(a). 
 174. Id. § 333.26423(q). 
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In addition, the individual must be over 18 years of age, with an 
exception for patients whose parents have fulfilled additional 
requirements.175 Once an individual has submitted their application, 
accurately, and in accordance with the department’s requirements, they 
must then be issued a patient identification card within five days of 
approval.176 An application may be denied only if the applicant failed to 
provide all the required portions of the application, or provided false 
information.177 If an applicant specified a caregiver at the time of their 
application, a caregiver identification card will also be issued for their 
caregiver.178 The MMMA requires that a caregiver be at least 21 years of 
age, have no felony convictions within ten years of the application, and 
no convictions of an illegal drug or assaultive felony.179 Each licensed 
caregiver is permitted to care for up to five patients, and may possess 2.5 
ounces of usable marihuana and 12 plants per patient.180
b. Immunity & Defenses Provided Under the MMMA 
Section 4 of the MMMA states,  
A qualifying patient who has been issued and possesses a registry 
identification card is not subject to arrest, prosecution, or penalty in any 
manner, or denied any right or privilege, including but not limited to, 
civil penalty or disciplinary action by a business or occupational or 
professional licensing board or bureau, for the medical use of 
marihuana in accordance with this act.181
However, in order to receive this immunity from arrest, a patient must 
have “both his or her registry identification card and a valid driver[‘s] 
license or government-issued identification card” with their image to 
show to the officer.182 Furthermore, if the patient possesses in excess of 
 175. Id. § 333.26426(b). 
 176. MMMA, § 333.26426(e). 
 177. Id. § 333.26426(c). 
 178. Id. § 333.26426(d). 
 179. Id. § 333.26423(k). 
 180. Id. § 333.26424. 
 181. Id. § 333.26424(a). 
 182. MMMA, § 333.26424(a) (emphasis added). 
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his or her allowable 2.5 ounces or 12 plants, they are not permitted this 
immunity.183 Similarly,  
A primary caregiver who has been issued and possesses a registry 
identification card is not subject to arrest, prosecution, or penalty in any 
manner, or denied any right or privilege, including but not limited to 
civil penalty or disciplinary action by a business or occupational or 
professional licensing board or bureau, for assisting a qualifying patient 
to whom he or she is connected through the department’s registration 
process with the medical use of marihuana in accordance with this 
act.184
Likewise, the caregiver must also have their registration card and 
photo ID, and be in strict compliance with the amount of usable 
marihuana and number of plants in their possession.185 Further, Section 4 
provides a presumption that a patient or caregiver is in possession of 
marihuana for medical purposes as long as they have their registration 
card and do not exceed their permitted amount of marihuana.186
However, this presumption may be rebutted by evidence showing 
otherwise.187 It is also important to note that section 4 of the MMMA 
provides an immunity for a person who “provid[es] a registered 
qualifying patient or . . . primary caregiver with marihuana paraphernalia 
for purposes of a qualifying patient’s medical use of marihuana,”188 as 
well as a person who is “in the presence or vicinity of the medical use of 
marihuana . . . or for assisting . . . with using or administering [medical] 
marihuana.”189
Though Section 4 affords immunities for the medical provision of 
marihuana, it also specifies consequences for those who disregard the 
limitations of the MMMA.190 As such, if a registered patient or caregiver 
sells marihuana to a person for the purposes of recreational marihuana 
use, their registration may be revoked and they may be “guilty of a 
 183. See id.
 184. Id.
 185. Id. § 333.26424(b). 
 186. Id. § 333.26424(e). 
 187. Id.
 188. MMMA, § 333.26424(h). 
 189. Id. § 333.26424(j). 
 190. Id. § 333.26424(l), 
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felony punishable by imprisonment for not more than 2 years or a fine of 
not more than $2,000.00, or both, in addition to any other penalties for 
the distribution of marihuana.”191 In the event a licensed patient, 
caregiver, or unlicensed individual is not in compliance with section 4 of 
the MMMA, but does not explicitly disregard the Act, they may still be 
provided a defense under Section 8 of the Act.192
Section 8 of the MMMA states:  
a patient and a patient’s primary caregiver, if any, may assert the 
medical purpose for using marihuana as a defense to any prosecution 
involving marihuana, and this defense shall be presumed valid where 
the evidence shows that: 
(1) A physician has stated that, . . . after having completed a full 
assessment of the patient’s medical history and current medical 
condition made in the course of a bona fide physician-patient 
relationship, the patient is likely to receive therapeutic or palliative 
benefit from the medical use of marihuana to treat or alleviate the 
patient’s serious or debilitating medical condition or symptoms of . . . ; 
(2) The patient and the patient’s primary caregiver, if any, were 
collectively in possession of a quantity of marihuana that was not more 
than was reasonably necessary to ensure the uninterrupted 
availability of marihuana for the purpose of treating or alleviating the 
patient’s serious or debilitating medical condition or symptoms of the 
patient’s . . . condition; and 
(3) The patient and the patient’s primary caregiver, if any, were 
engaged in the acquisition, possession, cultivation, manufacture, use, 
delivery, transfer, or transportation of marihuana . . . [for medical use 
only].193
An individual may assert this defense and is entitled to have the 
charges dropped after showing the above elements at an evidentiary 
hearing.194 In other words, Section 8 provides a defense for individuals 
who can show the amount of marihuana they possessed was reasonable,
 191. Id.
 192. Id. § 333.26428 
 193. Id. § 333.26428 (emphasis added). 
 194. MMMA, § 333.26428. 
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only for medical use, and that a physician, through a bona fide patient 
relationship, believed they would receive therapeutic or palliative effects 
from medical marihuana use.195
The MMMA further addresses the potential federal preemption issue 
in Section 7(e) where it states, “[a]ll other acts and parts of acts 
inconsistent with this act do not apply to the medical use of marihuana as 
provided for by this act.”196 Section 3(f) further defines “medical use” to 
include “the acquisition, possession . . . transfer, or transportation of 
marihuana.”197
c. Judicial Interpretation 
The Michigan Medical Marihuana Act is not a lengthy Act, and 
consequently defendants have often had to rely on judicial interpretation 
to determine their fate. In the short time the MMMA has been in effect, 
several cases have been in front of Michigan Judiciaries for clarification.  
In Ter Beek v. City of Wyoming, the Michigan Supreme Court held 
that the Federal Controlled Substances Act (CSA) did not preempt the 
Michigan Medical Marihuana Act.198 Further, the Court held that the City 
of Wyoming’s local ordinance prohibiting the use of land for any 
purpose “contrary to federal law” was in direct conflict with and 
preempted by the MMMA.199
Initially, the prosecutorial interpretation of the MMMA laws believed 
there could be no affirmative defense of compliance with Section 8 
unless the elements of Section 4 were satisfied.200 Luckily, the Michigan 
Supreme Court fixed this discrepancy with People v. Kolanek.201 The 
Court in Kolanek held that, when a defendant asserts their Section 8 
 195. Id.
 196. Id. § 333.26427(e). 
 197. Id. § 333.26423(f) (emphasis added). 
 198. Ter Beek v. City of Wyoming, 846 N.W.2d 531, 534 (Mich. 2014). 
 199. Id.
 200. People v. Redden, 799 N.W.2d 184, 192–93 (Mich. Ct. App. 2010) 
(“Nevertheless, the prosecution argues that the affirmative defense under § 8 is 
unavailable to defendants because they did not possess valid registry identification cards 
at the time of the offense, in violation of § 4.”). 
 201. People v. Kolanek, 817 N.W.2d 528, 540–41 (Mich. 2012). 
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defense, the defendant has a right to an evidentiary hearing on said 
Section 8 defense.202 In order  
to establish the elements of the affirmative defense in § 8, a defendant 
need not establish the elements of § 4. Any defendant, regardless of 
registration status, who possesses more than 2.5 ounces of usable 
marijuana or 12 plants not kept in an enclosed, locked facility may 
satisfy the affirmative defense under § 8. As long as the defendant can 
establish the elements of the § 8 defense and none of the circumstances 
in § 7(b) exists, that defendant is entitled to the dismissal of criminal 
charges.203
Kolanek provided a step in the right direction for the clarification of 
the Act’s intent to protect all who are medical marihuana users, not just 
those who are registered with LARA. As the Court stated, “The stricter 
requirements of § 4 are intended to encourage patients to register with 
the state and comply with the act in order to avoid arrest and the 
initiation of charges and obtain protection for other rights and 
privileges.”204 Though, if an individual does not register or is not in strict 
compliance with Section 4, they are still entitled to a defense.205
Individuals who are not eligible for Section 4 defenses are entitled to 
an affirmative defense under Section 8 of the MMMA.206 In People v. 
Hartwick, the Michigan Court of Appeals concluded that a Section 8 
defense “specifies three elements that an MMMA defendant must 
demonstrate before he can assert this defense.”207 The three elements that 
a defendant must demonstrate are: (1) proof of a bona fide physician-
patient relationship under § 8(a)(1); (2) proof of the caregiver’s 
awareness of the quantity of marijuana the patient is supposed to receive 
and for what period of time the patient should be prescribed marijuana; 
and lastly (3) whether or not the marijuana that is provided by the 
caregiver is “actually being used by the patient for medical reasons.”208
 202. Id. at 546. 
 203. Id. at 540–41. 
 204. Id. at 540. 
 205. Id.
 206. See People v. Hartwick, 842 N.W.2d 545, 547 (Mich. Ct. App. 2013). 
 207. Id. at 552. 
 208. Id. at 553. 
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The bona fide physician-patient relationship would be proved by 
presenting evidence that a
physician has stated that, in the physician’s professional opinion, after 
having completed a full assessment of the patient’s medical history and 
current medical condition made in the course of a bona fide physician-
patient relationship, the patient is likely to receive therapeutic or 
palliative benefit from the medical use of marihuana to treat or alleviate 
the patient’s serious or debilitating medical condition or symptoms of 
the patient’s serious or debilitating medical condition.209
The court detailed the boundaries of what a bona fide physician-
patient relationship would entail and reasoned that the “mere possession 
of a patient’s or caregiver’s identification card does not satisfy the first 
element of a § 8(a)’s affirmative defense.”210 The second element of the 
Section 8 affirmative defense requires that the patient and the patient’s 
primary caregiver are not collectively in possession of a quantity of 
marihuana that is more than reasonably necessary for the patient’s 
treatment.211 A defendant must prove that he is “intimately aware of 
exactly how much marijuana is required to treat a patient’s condition, 
which he learns from a doctor with whom the patient has an ongoing 
relationship.”212 The court held that “the amounts permitted in § 4 do not 
define what is ‘reasonably necessary’ to establish the § 8 defense.”213 The 
third and final element a defendant must prove for an affirmative defense 
under Section 8 would be a presentation of evidence that the patient 
actually used marihuana in a medical fashion prescribed under the 
MMMA; a mere state-issued registry identification card would not prove 
that the holder of the card subsequently “used” marihuana for medical 
purposes.214 Although exacting, the court’s decision in Hartwick proved 
to be a definitive guide as to what situations would give rise to a 
successful affirmative defense under Section 8 of the MMMA. 
 209. Id. 
 210. Id. at 555. 
 211. Id.  
 212. Hartwick, 842 N.W.2d at 556. 
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Even though the MMMA allows for caregivers to supply their patients 
with medical marihuana through transfer or sale, the Michigan Supreme 
Court held in State v. McQueen that “§4 of the MMMA, MCL 
333.26424, does not permit a registered qualifying patient to transfer 
marijuana for another registered qualifying patient’s medical use.”215 In 
McQueen, the defendants had a business that facilitated patient-to-patient 
sales of marihuana.216 Although the defendants intended to “benefit the 
transferee patient’s debilitating medical condition or symptoms,”217 the 
Court found that the transfers did not qualify for immunity under Section 
4 of the MMMA because “they encompass marijuana-related conduct 
that is not for the purpose of alleviating the transferor’s debilitating
medical condition or its symptoms.”218 The Court interpreted that “using 
or administering marijuana” under Section 4(i) would permit a “spouse 
of a registered qualifying patient to assist the patient in ingesting 
marijuana,”219 however it would not permit the assistance the defendants 
have provided to patients in acquiring marihuana in this case.220 The 
narrow interpretation of the Court’s decision with regards to “using 
marijuana” was later broadened in the iconic case of People v. Mazur.221
In People v. Mazur, the defendant Cynthia Mazur helped her husband 
David, who was both a registered qualifying patient and primary 
caregiver for two medical marijuana patients, by “writing the date of 
harvest for marijuana plants on several sticky notes.”222 The Court 
focused on the definition of “paraphernalia” based on the legislation 
behind the MMMA and came to the conclusion that paraphernalia 
encompassed both items specifically designed for marihuana use and 
items actually used in the course of ingesting marihuana.223 Thus, 
anything that was actually was used to aid “a qualifying patient’s 
transfer, delivery, acquisition, or cultivation of marijuana is a medical 
use according to a plain-language reading of the statute” and is also 
 215. State v. McQueen, 828 N.W.2d 644, 657 (Mich. 2013). 
 216. Id. at 646. 
 217. Id. at 655. 
 218. Id. 
219. Id. at 656. 
 220. Id. 
 221. People v. Mazur, 872 N.W.2d 201 (Mich. 2015). 
 222. Id. at 203. 
 223. Id. at 208. 
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paraphernalia.224 Mazur’s sticky notes were considered “marihuana 
paraphernalia” because “the objects were actually used in the cultivation 
or manufacture of marijuana” by detailing which plants would be 
harvested at what time.225 The Court held that the sticky notes fell within 
the scope of § 4(g) of the MMMA and the prosecution was “prohibited 
from introducing or otherwise relying on the evidence relating to [the] 
defendant’s provision of marijuana paraphernalia . . . as a basis for the 
criminal charges against [the] defendant.”226 Section 4(g) of the MMMA 
states that  
A person shall not be subject to arrest, prosecution, or penalty in any 
manner, or denied any right or privilege, including but not limited to 
civil penalty or disciplinary action by a business or occupational or 
professional licensing board or bureau, for providing a registered 
qualifying patient or a registered primary caregiver with marihuana 
paraphernalia for purposes of a qualifying patient’s medical use of 
marihuana.227
The effect of this holding demonstrates that the Court has understood 
this provision of the MMMA to be broadly construed in favor of a 
patient’s or caregiver’s medical use of marihuana.  
Another controverted portion of the MMMA centers on the ways in 
which a medical marihuana patient must ingest their medicine, and in 
which consumable forms the marihuana is permitted. In Carruthers, a 
medical marihuana patient, and caregiver, was found with brownies 
containing THC in his possession and subsequently was charged and 
convicted of possession with intent to deliver marijuana.228 The 
defendant appealed this conviction.229 In their original analysis of 
whether those brownies were considered marihuana, The Michigan Court 
of Appeals noted,  
The definition [of marihuana under the MMMA] specifically excludes 
the ‘mature stalks’ of the plant ‘except the resin extracted therefrom.’ 
 224. Id. 
 225. Id. at 209. 
 226. Id. 
 227. MICH. COMP. LAWS §333.26424(g) (2008).  
 228. See People v, Carruthers, 837 N.W.2d 16, 19 (Mich. Ct. App. 2013).
 229. Id. at 20. 
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By virtue of that exception, therefore, resin extracted from mature 
stalks is also expressly included within the definition of ‘marihuana.’ 
There is no dispute that both the raw marijuana and the brownies found 
in defendant’s possession constitute marijuana under the MMMA.230
However, the Court of Appeals then discussed the MMMA’s 
definition of usable marihuana, which does not include all parts of the 
plant.231 Specifically, under the MMMA’s definition of usable 
marihuana, the resin of the plant is not included, nor is every mixture or 
preparation.232 Thus, the Court of Appeals held that in order to 
“constitute usable marijuana under the MMMA, any mixture or 
preparation must be of the dried leaves or flowers of the marijuana 
plant.”233 The Court of Appeals relied on statutory interpretation and 
failed to take into account the fact that the MMMA was created by a 
voter referendum, with the purpose of “allow[ing] under state law the 
medical use of marihuana; [and] to provide protections for the medical 
use of marihuana.”234 The sole purpose of the act was to permit the use of 
medical marihuana, not to create a confusing regulation designed to trap 
medical patients in technicalities and accidental violations. Ultimately, 
the defendant in Carruthers was not afforded a protection under the 
MMMA because the marihuana he possessed within the brownies was 
not considered usable marihuana based on the court’s analysis.235
d. Newly Enacted Legislation to the Michigan Medical 
Marihuana Act 
The Michigan legislature has passed a package of bills in an effort to 
reform the current medical marihuana laws. Enrolled House Bill No. 
4209, also known as the “Medical Marihuana Facilities Licensing Act” 
was approved by the governor of Michigan, Rick Snyder, on September 
21, 2016 and sets up a new scheme legalizing, licensing, and regulating 
commercial medical marihuana growing, commercial medical marihuana 
 230. Id. at 22 (internal citations omitted). 
 231. Id.
 232. Id.
 233. Id. at 23. (internal quotations omitted). 
 234. MICH. COMP. LAWS §333.26424 (2008), Refs & Annos. 
 235. Carruthers, 837 N.W.2d at 18–19. 
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processing (creating edibles, oils, and other medical marihuana infused 
products), medical marihuana provisioning centers (otherwise known as 
dispensaries), safety compliance facilities, and secured transporters for 
the transportation of the medical marihuana or associated products.236
This would create a very highly regulated scheme that would not directly 
affect the Michigan Medical Marihuana Act; however, it would have far 
reaching consequences on the state’s medical marijuana producers and 
users.
The Act creates a system of checks and balances to ensure safe 
consumption of medical marihuana, from seed to sale. First, a medical 
marihuana licensing board of bi-partisan members appointed by the 
governor will be created to ensure the Act is implemented effectively, 
with the board members’ responsibilities consisting of licensing, 
regulating, and enforcing the regulations throughout the state.237 Other 
duties of the board include: providing oversight of a marihuana facility; 
implementing and collecting the application fees, taxes and regulatory 
assessments for licensees; and ensuring compliance by licensees in 
accordance with health and safety standards involved with marihuana-
infused products.238 An advisory panel, consisting of seventeen members 
from different occupations in relation to medical marihuana or law 
enforcement, will be formed to recommend rules regarding the 
administration, implementation, and enforcement of the act to the 
board.239
A licensee under the Act must apply for a growing license, secured 
transport license, processing license, safety compliance license, or 
provision center license.240 A growing license comes in three different 
classes, each prescribing a maximum number of plants that can be grown 
in a growing facility.241 A safety compliance facility will test marihuana 
to ensure the patients of Michigan receive unadulterated and chemical-
free medical marihuana.242 The secured transporter license “authorizes 
the licensee to store and transport marihuana and money associated with” 
 236. 2016 Mich. Pub. Acts 281. 
 237. Id. § 302. 
 238. Id. § 302(e)–(h). 
 239. Id. § 801. 
 240. Id. § 201. 
 241. Id. § 501(1). 
 242. 2016 Mich. Pub. Acts 281, § 505. 
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all of the different licensed entities among the Act.243 Through a secured 
transport, the grower and the other different inter-connected entities of 
marihuana facilities may transfer marihuana or seeds amongst each other, 
but must comply with the rules set forth in the Act.244 A processing 
center extracts resin from marihuana provided by a grower and creates 
marihuana-infused products in compliance with the Act.245 A 
provisioning center is similar to medical marihuana “dispensaries” 
located throughout the state; except the provisioning center is statutorily
allowed to sell to both registered qualifying caregivers and patients.246
This facility can sell both marihuana and marihuana-infused products, 
which were previously held to not qualify as “usable marihuana.”247 This 
new legislation provides for a bountiful source of revenue in the form of 
application fees, regulatory assessments, local and state licensing fees, 
and taxes.248 A new tax will be imposed on the provisioning centers 
throughout the state at the rate of three percent of gross retail receipts.249
These new sources of revenue will go towards municipalities and 
counties in which a marihuana facility is located, the state treasury, the 
Worker’s Disability Compensation Act of 1969, and law enforcement 
agencies.250
Enrolled House Bill No. 4210 was passed by the Michigan Senate on 
September 8, 2016, signed by the governor on September 21, and will be 
effective on December 20, 2016.251 The bill will amend the Michigan 
Medical Marihuana Act and allow for marihuana infused products to fall 
within the definition of usable marihuana under the Michigan Medical 
Marihuana Act and therefore receive immunity protections under the 
Act.252 It would also expand the definition of medical use in order to 
cover actions consistent with extracting and processing the marihuana 
 243. Id. § 503(1). 
 244. Id.
 245. Id. § 502. 
 246. Id. § 504. 
 247. See People v. Carruthers, 837 N.W.2d 16, 26 (Mich. Ct. App. 2013). 
 248. 2016 Mich. Pub. Acts 281 §§ 601–02. 
 249. Id. § 601. 
 250. Id. § 602. 
 251. House Bill 4210 (2015) History, MICHIGAN LEGISLATURE,
http://www.legislature.mi.gov/(S(y1ro2pulgrh21ybnuocb2bpt))/mileg.aspx?page=GetObj
ect&objectname=2015-HB-4210 (last visited Apr. 4, 2017). 
 252. See 2016 Mich. Pub. Acts 283. 
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plant.253 The Act also allows for a person under the age of eighteen who 
has a debilitating condition to be a registered qualifying patient as long 
as their parent or legal guardian, submits a written certification from two 
physicians; consents in writing to “allow the . . . patient’s medical use of 
marihuana; [s]erve[s] as the qualifying patient’s primary caregiver[,] 
and[;] [c]ontrol[s] the acquisition of the marihuana, the dosage, and the 
frequency of the medical use of marihuana by the qualifying patient.”254
The intent of the legislature is to streamline the industry with acceptable 
standards to benefit anyone who needs to use medical marihuana, while 
also limiting the risk involved with the abuse of medicinal marihuana. 
For example, similar to alcohol and tobacco regulations, the new act will 
establish restrictions on: marihuana-infused products that are shaped to 
appeal to minors, daily purchasing limits, marketing and advertising, and 
maximum tetrahydrocannabinol (THC) levels for marihuana-infused 
products.255
Finally, Michigan House Bill 4827256 passed by the Michigan Senate 
on September 8, 2016, will require all licensees under Senate Bill 4209 
to use an approved software for the seed to sale tracking of all marijuana 
and marijuana related products of any kind.257 In order to comply with 
the rules promulgated by Senate Bill 4209 a licensee would have to 
comply with rules promulgated in House Bill 4287.258
This Act, also known as the “Marihuana Tracking Act,” will monitor 
the medical use of marihuana more efficiently. The Marihuana Tracking 
Act will ensure that the state has access to all of the medical marihuana 
being grown, transported, processed, rejected, sold and consumed by 
implementing a statewide “integrated marihuana tracking, inventory, and 
verification system.”259 This system will allow law enforcement agencies 
and authorized state departments and agencies to “verify[] registry 
identification cards,” track the transfer and transportation of marihuana 
 253. Id. § 3(h). 
 254. Id. § 6(b). 
 255. 2016 Mich. Pub. Acts 281 § 206(o)–(q), (s). 
 256. 2016 Mich. Pub. Acts 282.  
 257. See id.; see also House Bill 4827 History, MICHIGAN LEGISLATURE,
http://www.legislature.mi.gov/(S(iu52yi4ct2egvnxtj5aql2er))/mileg.aspx?page=GetObjec
t&objectname=2015-HB-4827 (last visited Apr. 3, 2017).  
 258. See 2016 Mich. Pub. Acts 282. 
 259. Id. § 3(1). 
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between licensees, and verify that transfers will not exceed the limit a 
registered patient or caregiver is authorized to receive under Section 4 of 
the MMMA.260 The system will provide real-time updates which would 
show that a patient’s or primary caregiver’s registry card is valid or 
invalid, which has been a concern of law enforcement agencies and those 
who must medically use marihuana since the beginning of the MMMA’s 
enactment.261
Most importantly, the system will provide data regarding the “date, 
time, quantity, and price of each sale or transfer of marihuana to a 
registered qualifying patient or registered primary caregiver,” and 
“[e]ffective monitoring of marihuana seed-to-sale transfers.”262 The aim 
of this system is to fight fraudulent and black-market transactions from 
occurring due to the abuse or reckless disregard for the newly-enacted 
act.
A safeguard of privacy aimed to enshroud any participant’s 
involvement of the system is enabled in Section 4 of the Act. It protects 
the participant’s privacy by exempting information in the system from 
disclosure under the Freedom of Information Act.263 However, the 
information is not completely confidential. The act continues, stating 
“[i]nformation in the system may be disclosed for purposes of enforcing 
this act; the Michigan medical marihuana act . . . and the medical 
marihuana facilities licensing act.”264
The Act took effect on December 20, 2016.265 It is the Michigan 
legislature’s response to the issues regarding the vagueness and 
obscurities with the MMMA and its modern application, specifically to 
“provide immunity from prosecution for marihuana-related offenses for 
persons engaging in marihuana-related activities in compliance with this 
act.”266 The people of Michigan have seen the ways in which the initial 
MMMA laws have been interpreted adversely to patient’s and 
caregivers’ needs, such as in the case of People v. Carruthers.267 This 
 260. Id. § 2(g). 
261. Id. § 3(2)(a). 
 262. Id. § 3(2)(b), (d). 
 263. Id. § 4. 
 264. 2016 Mich. Pub. Acts 282, § 4. 
 265. See generally id. 
 266. 2016 Mich. Pub. Acts 281. 
 267. People v, Carruthers, 837 N.W.2d 16, 16 (Mich. Ct. App. 2013). 
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new Act will improve Michigan’s medical marihuana industry, 
illuminating the dark crevice of ambiguous judicial interpretation that 
has harmed the legislative intent of the MMMA and the patients it heals.  
e. Proposed Decriminalization of Marihuana in Michigan 
MILegalize, an organization which plans to introduce legislation in 
Michigan that would effectively legalize marihuana and its various uses, 
has recently been campaigning to decriminalize marihuana.268
Specifically, the aim of the legislation is to:  
legalize and regulate marihuana and hemp cultivation, production, 
testing, sale, distribution, possession, and use for medical and 
nonmedical purposes; to provide for licensing of certain marihuana 
establishments; to provide certain rights to persons with a doctor’s 
recommendation for the use of marihuana; to authorize collection of 
fees; to allow an excise tax on marihuana transfers at the point of sale; 
to provide for the powers and duties of certain state and local 
governmental officers and agencies; to authorize local units of 
government to adopt limited regulation of marihuana facilities and 
stores; and to require the promulgation of rules.269
Some details regarding the scope of the act involve: setting the 
minimum age of consumption to twenty-one (unless medically 
prescribed); defining medical marihuana as not only the bud of the 
flower but also in the form of oils, wax, tinctures, etc.; allowing the 
cultivation of marihuana plants; enacting a tax on marihuana sales, and; 
licensing marihuana stores and similar facilities.270
III. THE RELATIONSHIP BETWEEN CANADA AND MICHIGAN
Though the Marihuana for Medical Purposes Regulations and the 
Michigan Medical Marihuana Act have distinctly different 
concentrations in their written regulations, both Canada and Michigan 
share an understanding of the benefits its’ residents can receive from the 
 268. Read the Initiative!, MILEGALIZE, http://www.milegalize.com/read_the (last 
visited Apr. 3, 2017). 
 269. Id. 
 270. Id.  
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facilitation of medical marihuana use. In enacting the Marihuana Medical 
Access Regulations, Canada benefited its citizens by permitting them to 
use marihuana medically; aiding its citizens who were dealing with 
serious diseases such as cancer, multiple sclerosis, spinal cord injury, 
hepatitis, arthritis, as well as, anxiety, stress, depression, and pain.271
Michigan has almost identically understood and recognized the benefits 
its’ citizens would receive from using medical marihuana by enacting the 
MMMA, which allows patients to use medical marihuana for treating 
medical ailments such as “[c]ancer, glaucoma, [HIV], acquired immune 
deficiency syndrome, hepatitis C, amyotrophic lateral sclerosis, Crohn’s 
disease, agitation of Alzheimer’s disease, nail patella, or the treatment of 
these conditions.”272
Under Canada’s MMAR and Michigan’s MMMA, widely differing 
systems of regulation are utilized, with Canada reducing rights for home 
grows and focusing on commercial distribution and Michigan focusing 
on small production for a limited number of patients.273 In Canada, the 
cultivators must go through the process of obtaining a “Designated-
Person Production License” and in Michigan the cultivators are either 
patients or go through the process of becoming a “caregiver.”274
Although the terminology and initial licensing procedures may be 
different, the relationships between the cultivators and patients are very 
much the same, taking into consideration that there are many limits under 
both laws, such as limiting the number of plants to be cultivated to an 
apportioned amount, and specifics regarding the maximum amount of 
usable medical marihuana to be possessed by the cultivator at any given 
time.275
With recent changes in Canada’s medical marihuana legislation came 
the Marihuana for Medical Purposes Reform, which did not change 
many aspects about the previous law except for the cultivation 
requirements and allocations.276 It shifted the “Designated Person 
Production License” procedures to a more stable and regulated “licensed 
producers,” who had to undergo more extensive licensing procedures and 
 271. Legal Medical Cannabis Use in Canada, supra note 8. 
 272. MICH. COMP. LAWS §§ 333.26422(a) (2016).  
 273. See MMAR; see MMMA § 333.26424. 
 274. See MMAR, §38; see MMMA § 333.26424(a), (b).
 275. See MMAR, §34; see MMMA § 333.26424(a), (b). 
 276. MMPR, SOR/2013-119 (Can.). 
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who would be under stricter guidelines than the previous “designated 
person production license” holders.277 These guidelines include securing 
and enclosing a marihuana cultivation facility by means of video 
surveillance, gates and locks, and employing personnel to monitor the 
premises constantly.278 Under the MMMA, a caregiver who cultivates 
marihuana plants must keep them in an “enclosed, locked facility” and 
must not allow anyone other than himself or a registered qualifying 
patient to have unauthorized access to the enclosure.279 These two laws 
intend for the cultivation of medical marihuana to be in the control of 
those who are licensed as producers or caregivers, for practical reasons.  
Lastly, Michigan case law had previously determined that “edibles” 
and other marihuana-infused products for consumption are prohibited 
and not recognized under the MMMA as marihuana intended for 
“medical use.”280 In Canada, R. v. Smith the Supreme Court of Canada 
paved the way with ruling that the prohibition of the consumption of 
marihuana-infused products was disadvantageous to its’ intentions of 
allowing its citizens to benefit from the uses of all medical marihuana 
consumption.281 Although there are many similarities between 
Michigan’s and Canada’s medical marihuana laws, this difference 
between “usable marihuana” is a crucial tilting point that has recently 
pushed state senators to amend Michigan’s current MMMA laws with a 
further-reaching application of medical marihuana uses which now 
include marihuana-infused products for consumption and regulating 
state-wide sales of medical marihuana.282
IV. CONCLUSION 
It seems that the new set of bills in Michigan will, in many ways, 
imitate the commercial medical marihuana scheme set up in Canada 
 277. Id. pt. 1, div. 1, §12; Id. pt. 2, §34(1)(a). 
 278. Id. pt. 2, div. 3, §§ 41–48. 
 279. MICH. COMP. LAWS § 333.26424(a) (2016). 
 280. People v, Carruthers, 837 N.W.2d 16, 19 (Mich. Ct. App. 2013). 
 281. R. v. Smith, [2015] 2 S.C.R. 602 (Can.). 
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DETROIT NEWS (Sept. 8, 2016, 6:30 PM), 
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under the Marijuana for Medical Purposes Reform. If Michigan wants to 
follow in the footsteps of Canada it is important that they also learn from 
the mistakes that Canada has made. Canada now appears to be moving in 
the direction of full recreational legalization of marijuana throughout the 
country under the policies of new Prime Minister Justin Trudeau. 
Michigan should watch Canada closely as ballot initiatives like 
MILegalize are likely to legalize recreational cannabis use in Michigan 
in the near future. Canada’s recreational legalization should be looked at 
as an experiment for Michigan to learn from. Michigan does not have to 
copy Canada blindly, but rather should reject the policies that have failed 
so as to not make the same mistakes. 
 
